BioWorld Asia

Sep. 30, 2009

Qiagen's $130M Purchase of DxS a 13X Profit for Investors

LONDON - There was a record return for all the investors in companion diagnostics pioneer DxS Ltd., when the company was acquired last week by Qiagen NV for a total of up to $130 million. (BioWorld International) Read More

J&J Buys $444M Stake in Crucell; Focus on Flu Vaccine and mAbs

Repair Qualities of Macrophages, Hope for Muscle Regeneration

Rhucin Gains Ground as It Nears EMEA Action in HAE

NicOx Submits Naproxcinod's NDA; Celebrex in Crosshairs

Abbott Makes $6.6B Cash Bid for Solvay's Drug Unit

Marinomed, Bioalvo Collaborate on Drug Discoveries from the Sea

On the March: Vaccines Make it Big After H1N1 Scare

2009 Vaccine Deals

CHMP Gives Unanimous Backing for Yondelis in Ovarian Cancer

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 23, 2026.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.

Click chemistry drug bound to pancreatic cancer cells from mice

In vivo click ADCs could address tumor heterogeneity

BioWorld

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...